Predictive biomarkers for response to immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer.

被引：0
|
作者：
Stemmer, Amos [1 ]
Strauss, Gal [1 ]
Halpern, Naama [1 ]
Beller, Tamar [1 ]
Golan, Talya [1 ]
Margalit, Ofer [1 ]
Shacham-Shmueli, Einat [1 ]
Boursi, Ben [1 ]
机构：
[1] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [11] Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
    Stemmer, A.
    Margalit, O.
    Serpas, V.
    Strauss, G. Z.
    Thomas, J.
    Shash, P.
    Levanon, K.
    Shmueli, E. Shacham
    Kopetz, E. S.
    Overman, M. J.
    Boursi, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S447 - S447
  • [12] Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
    Vaghi, C.
    Ros Montana, F. J.
    Mambrilla, M.
    Navarro Garces, V.
    Comas, R.
    Salva Ballabrera, F.
    Baraibar Argota, I.
    Saoudi Gonzalez, N.
    Rodriguez Castells, M.
    Garcia Rodriguez, A.
    Alcaraz, A.
    Tabernero, J.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S56 - S57
  • [13] Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer
    Thomas, Jane
    Leal, Alexis
    Overman, Michael J.
    CLINICAL COLORECTAL CANCER, 2020, 19 (02) : 73 - 81
  • [14] ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer
    Piringer, Gudrun
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2025, 18 (01) : 26 - 29
  • [15] Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC).
    Leal, Alexis Diane
    Paludo, Jonas
    Finnes, Heidi D.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [16] Is it Time Yet for Adjuvant Immunotherapy for Patients with DNA Mismatch Repair Deficient Gastric Cancer?
    Jennifer R. Eads
    Annals of Surgical Oncology, 2022, 29 : 2141 - 2143
  • [17] Is it Time Yet for Adjuvant Immunotherapy for Patients with DNA Mismatch Repair Deficient Gastric Cancer?
    Eads, Jennifer R.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (04) : 2141 - 2143
  • [18] Tumor microbiome in subtypes of mismatch repair-deficient colorectal cancer.
    Joo, Jihoon E.
    Clendenning, Mark
    Mahmood, Khalid
    Rosty, Christophe
    Winship, Ingrid M.
    Jenkins, Mark A.
    Buchanan, Daniel D.
    CANCER RESEARCH, 2020, 80 (08) : 34 - 35
  • [19] Predictive biomarkers of response to cetuximab in Chinese patients with metastatic colorectal cancer
    Ma, Brigette
    Loong, Herbert
    Liem, Giok Siong
    Mo, Frankie
    Tong, Joanna
    Wong, S. C. Cesar
    Chan, Anthony T. C.
    To, Ka Fai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [20] Characteristics and survival of metastatic colorectal cancer patients receiving local treatment with deficient mismatch repair versus proficient mismatch repair
    Roodhart, J.
    Zwart, K.
    Punt, C. J. A.
    Wensink, E.
    Bolhuis, K.
    Lacle, M. M.
    van Grevenstein, W.
    Hagendoorn, J.
    de Hingh, I. H. J. T.
    Koopman, M.
    Vink, G.
    van der Baan, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S704 - S705
12345